Cargando…
Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine
In this phase 3 trial, Kampmann et al.(1) demonstrated safety and efficacy of a maternal bivalent RSV prefusion F vaccine. Vaccine efficacy was achieved in reducing severe RSV-associated lower respiratory tract infections in infants at 90 and 180 days following birth.
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313928/ https://www.ncbi.nlm.nih.gov/pubmed/37343524 http://dx.doi.org/10.1016/j.xcrm.2023.101081 |
| _version_ | 1785067211022401536 |
|---|---|
| author | Miller, Ann M. Varga, Steven M. |
| author_facet | Miller, Ann M. Varga, Steven M. |
| author_sort | Miller, Ann M. |
| collection | PubMed |
| description | In this phase 3 trial, Kampmann et al.(1) demonstrated safety and efficacy of a maternal bivalent RSV prefusion F vaccine. Vaccine efficacy was achieved in reducing severe RSV-associated lower respiratory tract infections in infants at 90 and 180 days following birth. |
| format | Online Article Text |
| id | pubmed-10313928 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103139282023-07-02 Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine Miller, Ann M. Varga, Steven M. Cell Rep Med Spotlight In this phase 3 trial, Kampmann et al.(1) demonstrated safety and efficacy of a maternal bivalent RSV prefusion F vaccine. Vaccine efficacy was achieved in reducing severe RSV-associated lower respiratory tract infections in infants at 90 and 180 days following birth. Elsevier 2023-06-20 /pmc/articles/PMC10313928/ /pubmed/37343524 http://dx.doi.org/10.1016/j.xcrm.2023.101081 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Spotlight Miller, Ann M. Varga, Steven M. Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine |
| title | Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine |
| title_full | Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine |
| title_fullStr | Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine |
| title_full_unstemmed | Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine |
| title_short | Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine |
| title_sort | fusing safety and efficacy: a maternal bivalent rsv prefusion f vaccine |
| topic | Spotlight |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10313928/ https://www.ncbi.nlm.nih.gov/pubmed/37343524 http://dx.doi.org/10.1016/j.xcrm.2023.101081 |
| work_keys_str_mv | AT millerannm fusingsafetyandefficacyamaternalbivalentrsvprefusionfvaccine AT vargastevenm fusingsafetyandefficacyamaternalbivalentrsvprefusionfvaccine |